| pubmed-article:17353369 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17353369 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:17353369 | lifeskim:mentions | umls-concept:C0037083 | lld:lifeskim |
| pubmed-article:17353369 | lifeskim:mentions | umls-concept:C0233820 | lld:lifeskim |
| pubmed-article:17353369 | lifeskim:mentions | umls-concept:C1710082 | lld:lifeskim |
| pubmed-article:17353369 | lifeskim:mentions | umls-concept:C0680243 | lld:lifeskim |
| pubmed-article:17353369 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17353369 | pubmed:dateCreated | 2007-3-20 | lld:pubmed |
| pubmed-article:17353369 | pubmed:abstractText | Chronic myeloid leukemia (CML), which is caused by the BCR-ABL fusion tyrosine kinase, is one of the most intensively studied human cancers. ABL kinase inhibitors have been spectacularly successful in treating CML, but disease persistence and acquired drug resistance can prevent eradication and cure of the leukemia. The development of better therapies will depend on a full understanding of signaling pathways in CML, facilitated by model studies using mutant mice. | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17353369 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17353369 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17353369 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17353369 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:17353369 | pubmed:issn | 0022-1007 | lld:pubmed |
| pubmed-article:17353369 | pubmed:author | pubmed-author:Van... | lld:pubmed |
| pubmed-article:17353369 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17353369 | pubmed:day | 19 | lld:pubmed |
| pubmed-article:17353369 | pubmed:volume | 204 | lld:pubmed |
| pubmed-article:17353369 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17353369 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17353369 | pubmed:pagination | 461-5 | lld:pubmed |
| pubmed-article:17353369 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:17353369 | pubmed:meshHeading | pubmed-meshheading:17353369... | lld:pubmed |
| pubmed-article:17353369 | pubmed:meshHeading | pubmed-meshheading:17353369... | lld:pubmed |
| pubmed-article:17353369 | pubmed:meshHeading | pubmed-meshheading:17353369... | lld:pubmed |
| pubmed-article:17353369 | pubmed:meshHeading | pubmed-meshheading:17353369... | lld:pubmed |
| pubmed-article:17353369 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17353369 | pubmed:articleTitle | Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. | lld:pubmed |
| pubmed-article:17353369 | pubmed:affiliation | Molecular Oncology Research Institute and the Division of Hematology/Oncology, Tufts-New England Medical Center, Boston, MA 02111, USA. rvanetten@tufts-nemc.org | lld:pubmed |
| pubmed-article:17353369 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17353369 | pubmed:publicationType | Comment | lld:pubmed |
| pubmed-article:17353369 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17353369 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17353369 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17353369 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17353369 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17353369 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17353369 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17353369 | lld:pubmed |
